An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel turned down emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for expanded access to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how regulators view specialty peptide therapies, which have drawn increasing interest from consumers seeking alternatives to standard drugs. Scientists say peptide treatments could change approaches to difficult infections, though concerns about consistency persist. The committee's endorsement of six peptides opens the door for more widespread prescribing, even as critics warn of long-term evidence. Market watchers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on particular peptide candidates.